Academic staff at Second Faculty of Medicine, Central Library of Charles University, First Faculty of Medicine, Third Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
Publications
- Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer2025 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Cell Reports Medicine Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers2025 | Second Faculty of Medicine, Central Library of Charles University
- Journal for ImmunoTherapy of Cancer Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v2025 | Second Faculty of Medicine
- Tissue contexture determines the pattern and density of tumor-infiltrating immune cells in HPV-associated squamous cell carcinomas of oropharynx and uterine cervix2024 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer2024 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma2023 | First Faculty of Medicine, Second Faculty of Medicine
- Trial watch: chemotherapy-induced immunogenic cell death in oncology2023 | Second Faculty of Medicine
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial2022 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
Loading network view...
